Workflow
毕得医药(688073.SH):2025年中报净利润为7340.61万元、较去年同期上涨41.60%

Core Insights - The company reported a total revenue of 628 million yuan for the first half of 2025, marking an increase of 95.32 million yuan compared to the same period last year, achieving a 17.91% year-on-year growth [1] - The net profit attributable to shareholders reached 73.41 million yuan, an increase of 21.57 million yuan from the previous year, reflecting a 41.60% year-on-year increase [1] - The company’s operating cash flow was 16.11 million yuan [1] Financial Ratios - The latest debt-to-asset ratio stands at 22.98%, a decrease of 0.84 percentage points from the previous quarter [3] - The gross profit margin is 44.25%, which is an increase of 4.75 percentage points compared to the same period last year [3] - The return on equity (ROE) is 3.77%, up by 1.14 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.84 yuan, an increase of 0.26 yuan, representing a 44.83% year-on-year growth [4] - The total asset turnover ratio is 0.25 times, an increase of 0.03 times from the previous year, achieving a 12.66% year-on-year growth [4] - The inventory turnover ratio is 0.43 times [4] Shareholder Structure - The number of shareholders is 3,782, with the top ten shareholders holding a total of 62.93 million shares, accounting for 69.25% of the total share capital [4] - The largest shareholder, Dai Lan, holds 32.64% of the shares [4]